E Lerma-Chippirraz1,2, Marta Pineda-Moncusí3, A González-Mena1, Jade Soldado-Folgado1,2, H Knobel1, M Trenchs-Rodríguez2, A Díez-Pérez1,2, Todd T Brown4, N García-Giralt3, R Güerri-Fernández1,2. 1. Infectious Diseases Department, Hospital del Mar Research Institute, Barcelona, Spain. 2. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Musculoskeletal Research Group, IMIM (Hospital del Mar Medical Research Institute), Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable (CIBERFES), ISCIII, Barcelona, Catalonia, Spain. 4. Department of Endocrinology, Johns Hopkins School of Medicine, Baltimore, MA, USA.
Abstract
BACKGROUND: The mechanisms behind ART-induced bone changes in HIV-infected patients are poorly known. We aimed to analyse changes in inflammatory and bone markers in HIV after tenofovir disoproxil fumarate initiation, and the associations with changes in the bone strength parameters. METHODS: HIV-positive participants starting tenofovir disoproxil fumarate-based ART underwent dual-energy X-ray absorptiometry (QDR 4500 SL®, Hologic, Waltham, MA, USA) for bone mineral density (BMD), a microindentation test (OsteoProbe®, Active Life Scientific, Santa Barbara, CA, USA) for bone quality [bone material strength index (BMSi)] and phlebotomy at baseline and 48 weeks after ART. A panel of inflammatory biomarkers and bone turnover markers were measured by ELISA. HIV-negative controls underwent identical procedures once. Values are expressed as medians and IQRs, and non-parametric tests were used to perform the analysis. RESULTS: Twenty HIV-infected individuals and 20 HIV-negative control individuals were matched in terms of age and gender. HIV individuals showed higher levels of inflammatory markers. We found no differences in bone turnover markers. HIV-positive individuals presented lower BMSi values at baseline compared with controls [86 (83-90) versus 89 (88-93), respectively; P = 0.034]. We found no difference in BMD (at either of the sites evaluated). BMSi tended to increase with treatment. IL-1β at baseline was positively correlated with changes in BMSi after ART (rho = 0.564, P = 0.014). Baseline levels of sclerostin tended to be negatively correlated with changes in BMSi (rho = -0.402, P = 0.097). We found a negative correlation between time since HIV diagnosis and changes in BMSi (rho = -0.466, P = 0.04). CONCLUSIONS: We observed a correlation between changes in bone quality and the inflammatory environment in HIV-positive individuals. Moreover, among the underlying mechanisms we highlight the Wnt pathway as having a potentially significant role in ART bone quality recovery.
BACKGROUND: The mechanisms behind ART-induced bone changes in HIV-infectedpatients are poorly known. We aimed to analyse changes in inflammatory and bone markers in HIV after tenofovir disoproxil fumarate initiation, and the associations with changes in the bone strength parameters. METHODS: HIV-positive participants starting tenofovir disoproxil fumarate-based ART underwent dual-energy X-ray absorptiometry (QDR 4500 SL®, Hologic, Waltham, MA, USA) for bone mineral density (BMD), a microindentation test (OsteoProbe®, Active Life Scientific, Santa Barbara, CA, USA) for bone quality [bone material strength index (BMSi)] and phlebotomy at baseline and 48 weeks after ART. A panel of inflammatory biomarkers and bone turnover markers were measured by ELISA. HIV-negative controls underwent identical procedures once. Values are expressed as medians and IQRs, and non-parametric tests were used to perform the analysis. RESULTS: Twenty HIV-infected individuals and 20 HIV-negative control individuals were matched in terms of age and gender. HIV individuals showed higher levels of inflammatory markers. We found no differences in bone turnover markers. HIV-positive individuals presented lower BMSi values at baseline compared with controls [86 (83-90) versus 89 (88-93), respectively; P = 0.034]. We found no difference in BMD (at either of the sites evaluated). BMSi tended to increase with treatment. IL-1β at baseline was positively correlated with changes in BMSi after ART (rho = 0.564, P = 0.014). Baseline levels of sclerostin tended to be negatively correlated with changes in BMSi (rho = -0.402, P = 0.097). We found a negative correlation between time since HIV diagnosis and changes in BMSi (rho = -0.466, P = 0.04). CONCLUSIONS: We observed a correlation between changes in bone quality and the inflammatory environment in HIV-positive individuals. Moreover, among the underlying mechanisms we highlight the Wnt pathway as having a potentially significant role in ART bone quality recovery.
Authors: Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Robert Güerri-Fernández; Elisabet Lerma-Chippirraz; Ana Fernandez Marron; Natalia García-Giralt; Judit Villar-García; Jade Soldado-Folgado; Alicia González-Mena; Marta Trenchs-Rodríguez; Ana Guelar; Adolfo Díez-Pérez; Todd T Brown; Hernando Knobel Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Frank Malgo; Neveen A T Hamdy; Socrates E Papapoulos; Natasha M Appelman-Dijkstra Journal: J Clin Endocrinol Metab Date: 2015-03-13 Impact factor: 5.958
Authors: Daniel Prieto-Alhambra; Robert Güerri-Fernández; Frank De Vries; Arief Lalmohamed; Marloes Bazelier; Jakob Starup-Linde; Adolfo Diez-Perez; Cyrus Cooper; Peter Vestergaard Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Adolfo Diez-Perez; Roberto Güerri; Xavier Nogues; Enric Cáceres; Maria Jesus Peña; Leonardo Mellibovsky; Connor Randall; Daniel Bridges; James C Weaver; Alexander Proctor; Davis Brimer; Kurt J Koester; Robert O Ritchie; Paul K Hansma Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Arnold Z Olali; Kelsey A Carpenter; Maria Myers; Anjali Sharma; Michael T Yin; Lena Al-Harthi; Ryan D Ross Journal: Curr HIV/AIDS Rep Date: 2022-06-20 Impact factor: 5.495
Authors: Yanhan Shen; Stephanie Shiau; Renate Strehlau; Megan Burke; Faeezah Patel; Cara T Johnson; Bridgette Rizkalla; Gallagher Dympna; Louise Kuhn; Ashraf Coovadia; Michael T Yin; Stephen M Arpadi Journal: AIDS Date: 2021-11-01 Impact factor: 4.632
Authors: Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra Journal: Front Endocrinol (Lausanne) Date: 2020-02-07 Impact factor: 5.555